Home > Haematology > EHA 2019 > Benign Haematology > Early trial data shows positive results for treating anaemia in patients with end-stage renal failure

Early trial data shows positive results for treating anaemia in patients with end-stage renal failure

Presented By
Prof. Lutz Renders, Klinikum Rechts der Isar, Germany
Conference
EHA 2019
A multicentre, randomised, double-blind, placebo-controlled, multiple ascending dose, pilot phase 2a study determined that PRS-080 is safe in anaemic stage 5 chronic kidney disease patients requiring haemodialysis. A haemoglobin (Hb) response with clear segregation of Hb values between placebo and PRS-080 in the 8 mg/kg cohort during the treatment period showed early efficacy, consisting of an increase of Hb in drug-treated patients and a decline in placebo patients, potentially related to the withdrawal of iron treatment [1]. Nephrologist Prof. Lutz Renders (Klinikum Rechts der Isar, Germany) explained that patients with chronic kidney disease (CKD) commonly present with anaemia. Current treatment regimens consist of iron, erythropoietin stimulating agents (ESAs), or both, but a significant proportion of patients remain anaemic despite the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on